Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Senti Biosciences (SNTI) Research & Development (2021 - 2025)

Senti Biosciences (SNTI) has 5 years of Research & Development data on record, last reported at $10.5 million in Q3 2025.

  • For Q3 2025, Research & Development rose 21.5% year-over-year to $10.5 million; the TTM value through Sep 2025 reached $38.5 million, up 21.77%, while the annual FY2022 figure was $28.1 million, 28.18% up from the prior year.
  • Research & Development reached $10.5 million in Q3 2025 per SNTI's latest filing, up from $10.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $11.0 million in Q2 2023 and bottomed at $5.0 million in Q3 2023.
  • Average Research & Development over 5 years is $8.2 million, with a median of $8.7 million recorded in 2024.
  • Peak YoY movement for Research & Development: tumbled 37.72% in 2023, then skyrocketed 72.51% in 2024.
  • A 5-year view of Research & Development shows it stood at $6.4 million in 2021, then grew by 9.8% to $7.0 million in 2022, then dropped by 28.71% to $5.0 million in 2023, then surged by 72.51% to $8.7 million in 2024, then grew by 21.5% to $10.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $10.5 million in Q3 2025, $10.0 million in Q2 2025, and $9.3 million in Q1 2025.